Caroline Baumal, M.D., serves as the Chief Medical Officer at Apellis Pharmaceuticals Inc., a biopharmaceutical company focused on developing innovative therapies for autoimmune and inflammatory diseases. Dr. Baumal brings a wealth of experience to her role, with a distinguished career in ophthalmology and a strong background in clinical research and drug development. She earned her medical degree from the University of Pennsylvania School of Medicine and completed her residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, followed by a fellowship in vitreoretinal surgery at the same institution. Throughout her career, Dr. Baumal has made significant contributions to the field of ophthalmology, particularly in the treatment of retinal diseases. She has published numerous peer-reviewed articles and has been actively involved in clinical trials that have advanced the understanding and management of conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. Her expertise in these areas has been instrumental in guiding Apellis Pharmaceuticals' development of novel therapies, including their flagship product, pegcetacoplan, which targets geographic atrophy secondary to AMD. As Chief Medical Officer at Apellis Pharmaceuticals, Dr. Baumal plays a crucial role in overseeing the company's clinical development programs and ensuring the safety and efficacy of their therapeutic candidates. Her leadership has been pivotal in advancing the company's pipeline and bringing innovative treatments to patients with unmet medical needs. Under her guidance, Apellis has made significant strides in clinical trials, positioning the company as a leader in the development of complement-targeted therapies for a range of autoimmune and inflammatory conditions.